[Congressional Record Volume 171, Number 34 (Thursday, February 20, 2025)]
[Senate]
[Page S1202]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 505. Ms. KLOBUCHAR submitted an amendment intended to be proposed 
by her to the concurrent resolution S. Con. Res. 7, setting forth the 
congressional budget for the United States Government for fiscal year 
2025 and setting forth the appropriate budgetary levels for fiscal 
years 2026 through 2034; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO RESEARCH 
                   AND PRODUCT REVIEWS BY THE FOOD AND DRUG 
                   ADMINISTRATION FOR RARE DISEASES.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     research and product reviews by the Food and Drug 
     Administration for rare diseases, which may include efforts 
     to accelerate the development and approval of treatments, 
     improvements in regulatory science, or support for research 
     on innovative therapies, by the amounts provided in such 
     legislation for those purposes, provided that such 
     legislation would not increase the deficit over the period of 
     the total of fiscal years 2025 through 2034.
                                 ______